Ancora.ai

📢 Help Improve NEN Cancer Care! 📌 Join the NEN RADAR Survey: https://lnkd.in/dU_KjGxQ 👉 Are you a NEN cancer patient or a healthcare professional treating NEN cancer with Peptide Receptor Radionuclide Treatment (PRRT)? We need your voice! The NEN RADAR Survey is gathering insights on: 1.    What do you know about PRRT? 2.    What’s your experience with PRRT? 3.    Can you access PRRT? ✔️ NEN RADAR Survey comes from SPARC Europe - committed to understanding how PRRT is understood, experienced, and accessed. Your input will shape evidence-based policy recommendations to ensure more patients can benefit from this life-saving treatment. 🌍 Your voice = Better access, better outcomes! Available in multiple languages including English, French, German, Spanish, and Italian. 👉 Take the survey now and make a difference in the future of NEN cancer care! Want to learn more or have any questions? Feel free to reach out to SPARC Europe at [email protected] #LetsTalkAboutNETs #NeuroendocrineCancer #NeuroendocrineNeoplasms 

Danielle Ralic rocking the stage at Digital Health day today by Swiss Healthcare startups Revolutionizing clinical trials recruitment with #AI #digitalhealth #eHealth

£50,000 grants up for grabs - because those with neuroendocrine cancer are less well represented in research and have less opportunities to benefit from novel advancements. Please RT: https://lnkd.in/d-3N9kgj Genomics England Rare Cancer Research Foundation Research & Innovation Department at Leeds Teaching Hospitals NHS Trust University of Exeter Faculty of Health and Life Sciences Edinburgh Medical School

And we're live at European Association of Nuclear Medicine (EANM)! Come stop by the ICPO Foundation-International Centers for Precision Oncology booth to get a demo of the Radiopharmaceutical Trial Finder edition of Ancora.ai: 📍 Hall 3, S33 The global #radiopharmaceutical #clinicaltrial finder tool enables anyone to quickly discover and explore trials. Not at #EANM24? Try the Ancora.ai Radiopharmaceutical Clinical Trial Finder for yourself: https://lnkd.in/dnsW2Guk

ICPO Foundation-International Centers for Precision Oncology Foundation funded global “Radiopharmaceutical Trial Finder” developed by WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) and Ancora.ai This pioneering global trial finder tool powered by AI will be presented at the European Association of Nuclear Medicine (EANM) Congress 2024 in Hamburg from Oct 20-22, 2024   October 16, 2024 – Wiesbaden, Germany and Zurich, Switzerland. Radiopharmaceuticals, a rapidly growing medical field, are revolutionizing patient care by offering innovative and precise diagnostic and therapeutic solutions. Despite their immense potential, keeping up with the ever-evolving landscape of radiopharmaceutical research can be challenging due to the rapid pace of advancements and the complexity of the underlying scientific concepts. To address these challenges, WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) and Ancora.ai with grant funding from the ICPO Foundation, collaborated to develop a novel, AI-powered global platform for radiopharmaceutical trials. The launch of the “Radiopharmaceutical Trial Finder” will be presented with a live demo at the prestigious European Association of Nuclear Medicine (EANM) Congress 2024 at ICPO booth S33 in Hall H, from Oct. 20-22, 2024. The entire team is grateful to the platform’s scientific advisors and their contributions to the pioneer platform’s development, in particular: Dr. Cathy Cutler, Dr. Andrew Scott, Dr. Ken Herrmann, Dr. Michael Hofman, Dr. Kalevi Kairemo, Dr. Elcin Zan, MD, Dr. Masha Maharaj and Bonnie Clarke.   Josh Mailman, Executive Board Member of WARMTH, stated: “Having such a platform will be transformative for clinical trials, as it not only increases accessibility for patients but also fosters greater collaboration across borders.”   Danielle Ralic, CEO of Ancora.ai, is delighted about the innovative project: “This tool represents a significant step forward for the radiopharmaceutical community. Our goal is to remove barriers in trial discovery and accelerate the pace of innovation in this critical field.”   Odile JAUME, CEO of the ICPO Foundation, expressed her enthusiasm about this highly valuable patient-centric initiative supported by an ICPO grant: “A significant breakthrough has been achieved offering new hope to cancer patients around the globe. This collaboration between patients, leading international clinicians, researchers and the ICPO Community has resulted in a powerful tool that opens the door for patients to increase their awareness and access life-saving clinical trials. We are proud that the ICPO grant has made this possible.” #ICPO #WARMTH #Ancoraai #EANM #Hamburg #MolecularImaging #Imaging #Diagnosis #Theranostics #RadiomolecularPrecisionOncology   ICPO Team: #RichardRichard P. Baum #OdileOdile JAUME #MarwaMarwa Hakkam #KarimKarim Bouterfa #SusanneSusanne Simon #AndreasAndreas Noetzold #KatjaKatja Schorn #MartinMartin Reuter

#Clinicaltrials are such an important topic. Thank you International Neuroendocrine Cancer Alliance for all the great work you do in raising awareness. We're so proud to partner with you on accessing #NET clinical trials with the digital trial finder tool. We encourage all affected by cancer to look for trials. It's always good to see what's being researched and trials can be treatment options. Explore NET trials with our free online trial finder today at INCA's Find a Trial resource - https://lnkd.in/dABv_heE #neuroendocrinetumors #neuroendocrinecancer #cancer #digitalhealth

At Ancora.ai, we work with best-in-class physicians, patient associations, and scientific experts to bridge the gap between innovations in medicine and patients. Radiopharmaceuticals are a rapidly evolving and promising field that has recently experienced a surge in investment and research. That’s why we’re so excited to share that on Oct. 20th we’re launching our Radiopharmaceutical Trials Platform in collaboration with WARMTH (https://warmth.org/) and with funding by ICPO Foundation-International Centers for Precision Oncology. The Radiopharmaceutical Trials Platform lets you explore #radiopharmaceutical trials from across the world by radiation emission type, radionuclide, target and more! A huge thank you to our scientific advisors and their valuable contributions to the project: Prof. Ken Herrmann, Prof. Andrew Scott, Elcin Zan, MD, Dr. Masha Maharaj, Dr. Kalevi Kairemo, Dr. Sze Ting Lee, Bonnie Clarke, Dr. Cathy Cutler, and Dr. Michael Hofman The official launch is on Oct. 20th, 2024 at the European Association of Nuclear Medicine (EANM) Congress. Stop by the ICPO booth at EANM (HALL 3, S33) to get a demo and/ or sign up below to be notified when the platform is live: https://lnkd.in/dnsW2Guk Lastly, a huge thank you to all the project members and their support: Josh Mailman, Odile JAUME, Susanne Simon, Karim Bouterfa, and Andreas Noetzold, Katie Vieyra, Danielle Ralic, Beatriz M. Monreal, Marko Buterin, mag. inf., Zvonimir Dražina. #clinicaltrials #clinicalresearch #nuclearmedicine #oncology #healthtech #innovation #AI #AIinhealthcare

"[In clinical trials] a very high percentage of identified and interested patients drop out of the funnel early on, prior to completing pre-screening." A pilot study explains why in this DIA Global Forum article co-authored by  Danielle R., Beatriz Monreal, Katie Vieyra, Ruby Ford, MPH and Ken Getz, and paves the way for "a larger empirical study to gather more robust data characterizing the magnitude of the “last mile” problem across disease conditions and identifying improvement opportunities." CALL TO ACTION: The authors "invite sponsors and contract research organizations to join us in this working group study to evaluate the “last mile” challenge, update the legacy recruitment funnel framework, and ultimately diversify and accelerate patient recruitment in clinical trials."